Combination therapy — a treatment approach used to target multiple pathways involved in pulmonary arterial hypertension (PAH) — improves hemodynamics (blood flow) in treatment-naïve patients, according to a new pooled analysis of several studies. A measure of the resistance to blood flow, called pulmonary vascular resistance (PVR), decreased significantly…
News
Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial. Results showed that the therapy improved blood flow in patients’ lungs, but did not affect blood pressure elsewhere in the body. “The promising pulmonary selectivity and…
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new subcutaneous or under-the-skin infusion pump for treprostinil — a generic form of Remodulin — for treating people with pulmonary arterial hypertension (PAH). The exclusive rights to promote and market treprostinil injection belong…
Treatment with seralutinib (GB002), an inhaled investigational therapy, significantly improved measures of blood pressure in the lungs of people with pulmonary arterial hypertension (PAH) in the Phase 2 TORREY study, meeting the trial’s main goal. Promising effects also were seen on measures of exercise capacity and heart structure, with these…
Researchers have created an automated way to engineer a more stable peptide-based therapy, which could inform the production of new and improved treatments for diseases like pulmonary arterial hypertension (PAH). The research was led by Yousef Al-Abed, PhD, co-director of the Institute of Bioelectronic Medicine at the Feinstein Institutes for…
Immune cells called eosinophils help protect against the progression of pulmonary hypertension (PH) by reducing lung inflammation and regulating the growth of muscle cells around blood vessels, a new study indicates. The study, “Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA,” was published in the …
The identified cause of pulmonary arterial hypertension (PAH) in patients seen at a specialized care center differed substantially from national registry data, a study revealed. Most care center patients were diagnosed with PAH associated with connective tissue disorders and exposure to toxins, whereas idiopathic PAH (IPAH), of unknown cause,…
Treatment with the approved therapy Uptravi (selexipag) safely reduces disease severity and improves heart and lung health in people with pulmonary hypertension (PH), according to a review study. Researchers recommended that Uptravi be considered for use in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic…
Obstructive sleep apnea (OSA) is common among people with pulmonary hypertension (PH), and PH patients with OSA are more likely to report co-occurring health problems like diabetes and high blood pressure, a new study done at a center in China reports. In fact, the study found that more than…
Step count and heart rate data from wearable sensors can be of use as real-world approximations of common clinical tests of fitness, a study drawing on data from people with pulmonary arterial hypertension (PAH) shows. “Activity tracker-measured health parameters could serve as proxies for clinically measured health parameters of…
Real-world use of Opsumit (macitentan) was generally safe, with few liver-related toxicities seen, according to data from two registries largely made up of pulmonary arterial hypertension (PAH) patients. Collective data from the two registries met a requirement from the U.S. Food and Drug Administration (FDA) for additional real-world safety…
A rare mutation in the GDF2 gene was identified in two siblings, a boy and a girl, with pulmonary arterial hypertension (PAH), according to a recent case report. The mutation, which each child inherited in both gene copies, resulted in a lack of the bone morphogenetic protein (BMP) 9 in the…
